Replies to post #228 on Pacific Biosciences of California Inc (PACB)

[Paulieme]

Saturday, October 19, 2013
Pacific Biosciences has been squeezing 454 in applications requiring long reads. My second (of two) 454 experiments was in de novo bacterial genome assembly, and some gain over pure Illumina was had -- but just after I got that dataset I got my first PacBio dataset with HGAP correction, and it was game over for any other current platform in that application. (A good article). http://omicsomics.blogspot.com/2013/10/ripples-from-454s-shutdown-announcment.html